[1]肖婷婷,石珂,缪振忠,等.临床抗青光眼药物的新进展[J].眼科新进展,2019,39(2):192-196.[doi:10.13389/j.cnki.rao.2019.0044]
　XIAO Ting-Ting,SHI Ke,MIAO Zhen-Zhong,et al.Novel advances in clinical on anti-glaucoma drug[J].Recent Advances in Ophthalmology,2019,39(2):192-196.[doi:10.13389/j.cnki.rao.2019.0044]
点击复制

临床抗青光眼药物的新进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年2期
页码:
192-196
栏目:
文献综述
出版日期:
2019-02-05

文章信息/Info

Title:
Novel advances in clinical on anti-glaucoma drug
作者:
肖婷婷; 石珂; 缪振忠; 李玉生; 李国栋
330006　江西省南昌市，南昌大学第二附属医院眼科
Author(s):
XIAO Ting-Ting; SHI Ke; MIAO Zhen-Zhong; LI Yu-Sheng; LI Guo-Dong
Department of Ophthalmology，the Second Hospital Affiliated to Nanchang University，Nanchang 330006，Jiangxi Province，China
关键词:
青光眼; 眼压; 临床随机对照研究; 药物治疗
Keywords:
glaucoma; intraocular pressure; clinical randomized controlled trial; medication
分类号:
R775
DOI:
10.13389/j.cnki.rao.2019.0044
文献标志码:
A
摘要:
青光眼是致盲的主要原因之一，构成视神经的神经节细胞轴突受到多种因素的损伤，其机制尚未完全明了。青光眼最重要的危险因素是眼压升高。由于青光眼的视神经损伤尚不能直接治疗，根据目前提供的唯一已知可治疗的危险因素，可以降低升高的眼压，而眼压与房水流出通道的功能息息相关。这些方面的药物均可以影响青光眼的进展。随着医疗技术的发展以及对青光眼发病机制认识的加深，新型抗青光眼药物也应运而生，为眼科医师提供新的选择。本文将对国内外新型抗青光眼药物从机制、药理特点及临床疗效等方面进行综述。
Abstract:
In glaucoma,the ganglion-cell axons that make up the optic nerve are damaged by a variety of factors,only some of which are understood.The most important risk factor for glaucoma is elevated intraocular pressure.Because the optic-nerve damage in glaucoma is not yet amenable to direct treatment,we provide treatment for the only known risk factors that can be modified the elevated intraocular pressure.However，the function of eye pressure is closely related to the function of the flow passage of the aqueous humor.As more is understood about the molecular biology of the trabecular meshwork and optic nerve in health and disease,the ability to treat glaucoma will likely improve.The new glaucoma drugs are also allowed to come into being.This review will focus on the mechanism,pharmacological characteristics and clinical efficacy of new anti-glaucoma drugs at home and abroad.

参考文献/References:

［1］　KWON Y H，FINGERT J H，KUEHN M H，ALWARD W L.Primary open-angle glaucoma［J］.N Engl J Med，2009，360(11):1113-1124.
［2］　HONJO M，INATANI M，KIDO N，SAWAMURA T，YUE B Y，HONDA Y，et al.Effects of protein kinase inhibitor，HA1077，on intraocular pressure and outflow facility in rabbit eyes［J］.Arch Ophthalmol，2001，119(8):1171-1178.
［3］　TORIS C B，MCLAUGHLIN M A，DWORAK D P，FAN S，HAVENS S，ZHAN G L，et al.Effects of Rho kinase inhibitors on intraocular pressure and aqueous humor dynamics in nonhuman primates and rabbits［J］.J Ocul Pharmacol Ther，2016，32(6):355-364.
［4］　SERLE J B，KATZ L J，MCLAURIN E，HEAH T，RAMIREZ-DAVIS N，USNER D W，et al.Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure［J］.Am J Ophthalmol，2018，186：116-127.
［5］　MAATTA M，TERVAHARTIALA T，HARJU M，AIRAKSINEN J，AUTIO-HARMAINEN H，SORSA T.Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma，exfoliation syndrome，and exfoliation glaucoma［J］.J Glaucoma，2005，14(1):64-69.
［6］　LERNER S F，PARK K H，HUBATSCH D A，ERICHEV V，PACZKA J A，ROBERTS T V.Efficacy and tolerability of travoprost 0.004%/Timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy［J］.J Ophthalmol，2017，2017:1917570.
［7］　WORDINGER R J，SHARMA T，CLARK A F.The role of TGF-beta2 and bone morphogenetic proteins in the trabecular meshwork and glaucoma［J］.J Ocul Pharmacol Ther，2014，30(2-3):154-162.
［8］　NOLAN M J，GIOVINGO M C，MILLER A M，WERTZ R D，RITCH R，LIEBMANN J M，et al.Aqueous humor sCD44 concentration and visual field loss in primary open-angle glaucoma［J］.J Glaucoma，2007，16(5):419-429.
［9］　SHPAK A A，GUEKHT A B，DRUZHKOVA T A，KOZLOVA K I，GULYAEVA N V.Brain-derived neurotrophic factor in patients with primary open-angle glaucoma and age-related cataract［J］.Curr Eye Res，2018，43(2):224-231.
［10］　ODDONE F，ROBERTI G，MICERA A，BUSANELLO A，BONINI S，QUARANTA L，et al.Exploring serum levels of brain derived neurotrophic factor and nerve growth factor across glaucoma stages［J］.PLoS One，2017，12(1):e168565.
［11］　NAMIKI M，TAGAMI Y，YAMAMOTO M，YAMANAKA A，ITOH M，KANOH M.Presence of human epidermal growth factor (hEGF)，basic fibroblast growth factor (bFGF) in human aqueous［J］.Nippon Ganka Gakkai Zasshi，1992，96(5):652-656.
［12］　GARTAGANIS S P，GEORGAKOPOULOS C D，EXARCHOU A M，MELA E K，LAMARI F，KARAMANOS N K.Increased aqueous humor basic fibroblast growth factor and hyaluronan levels in relation to the exfoliation syndrome and exfoliative glaucoma［J］.Acta Ophthalmol Scand，2001，79(6):572-575.
［13］　PARRILLA-REVERTER G，AGUDO M，SOBRADO-CALVO P，SALINAS-NAVARRO M，VILLEGAS-PEREZ M P，Vidal-Sanz M.Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury:a quantitative in vivo study［J］.Exp Eye Res，2009，89(1):32-41.
［14］　LEBRUN-JULIEN F，DI POLO A.Molecular and cell-based approaches for neuroprotection in glaucoma［J］.Optom Vis Sci，2008，85(6):417-424.
［15］　LEVKOVITCH-VERBIN H，VANDER S，MAKAROVSKY D，LAVINSKY F.Increase in retinal ganglion cells’ susceptibility to elevated intraocular pressure and impairment of their endogenous neuroprotective mechanism by age［J］.Mol Vis，2013，19:2011-2022.
［16］　CHI W，LI F，CHEN H，WANG Y，ZHU Y，YANG X，et al.Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1beta production in acute glaucoma［J］.Proc Natl Acad Sci U S A，2014，111(30):11181-11186.
［17］　WAN P，SU W，ZHANG Y，LI Z，DENG C，ZHUO Y.Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway［J］.Clin Sci (Lond)，2017，131(18):2363-2375.
［18］　GOMES E，PAPA L，HAO T，ROCKWELL P.The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells［J］.Mol Cell Biochem，2007，305(1-2):179-190.
［19］　KILIC U，KILIC E，JARVE A，GUO Z，SPUDICH A，BIEBER K，et al.Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways［J］.J Neurosci，2006，26(48):12439-12446.
［20］　FOXTON R H，FINKELSTEIN A，VIJAY S，DAHLMANN-NOOR A，KHAW P T，MORGAN J E，et al.VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma［J］.Am J Pathol，2013，182(4):1379-1390.
［21］　PROKAI-TATRAI K，XIN H，NGUYEN V，SZARKA S，BLAZICS B，PROKAI L，et al.17beta-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma［J］.Mol Pharm，2013，10(8):3253-3261.
［22］　DANESH-MEYER H V.Neuroprotection in glaucoma:recent and future directions［J］.Curr Opin Ophthalmol，2011，22(2):78-86.
［23］　YANG F，WANG D，WU L，LI Y.Protective effects of triptolide on retinal ganglion cells in a rat model of chronic glaucoma［J］.Drug Des Devel Ther，2015，9:6095-6107.
［24］　STOILOV I，AKARSU A N，SARFARAZI M.Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21［J］.Hum Mol Genet，1997，6(4):641-647.
［25］　MOROI S E，RAOOF D A，REED D M，ZOLLNER S，QIN Z，RICHARDS J E.Progress toward personalized medicine for glaucoma［J］.Expert Rev Ophthalmol，2009，4(2):145-161.
［26］　MCLAREN N C，MOROI S E.Clinical implications of pharmacogenetics for glaucoma therapeutics［J］.Pharmacogenomics J，2003，3(4):197-201.
［27］　ROCHA-SOUSA A，RODRIGUES-ARAUJO J，GOUVEIA P，BARBOSA-BREDA J，AZEVEDO-PINTO S，PEREIRA-SILVA P，et al.New therapeutic targets for intraocular pressure lowering［J］.ISRN Ophthalmol，2013，2013:261386.
［28］　WANG W H，MCNATT L G，PANG I H，MILLAR J C，HELLBERG P E，HELLBERG M H，et al.Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure［J］.J Clin Invest，2008，118(3):1056-1064.
［29］　LEWIS R A，CHRISTIE W C，DAY D G，CRAVEN E R，WALTERS T，BEJANIAN M，et al.Bimatoprost sustained-release implants for glaucoma therapy:6-month results from a phase Ⅰ/Ⅱ clinical trial［J］.Am J Ophthalmol，2017，175:137-147.
［30］　ANDERS F，TEISTER J，LIU A，FUNKE S，GRUS F H，THANOS S，et al.Intravitreal injection of beta-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma［J］.PLoS One，2017，12(4):e175451.
［31］　HERMANN M M，PAPACONSTANTINOU D，MUETHER P S，GEORGOPOULOS G，DIESTELHORST M.Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring［J］.Acta Ophthalmol，2011，89(4):e300-e305.
［32］　NATU M V，GASPAR M N，FONTES R C，CABRITA A M，DE SOUSA H C，GIL M H.In vitro and in vivo evaluation of an intraocular implant for glaucoma treatment［J］.Int J Pharm，2011，415(1-2):73-82.
［33］　HACKER M C，HAESSLEIN A，UEDA H，FOSTER W J，GARCIA C A，AMMON D M，et al.Biodegradable fumarate-based drug-delivery systems for ophthalmic applications［J］.J Biomed Mater Res A，2009，88(4):976-989.
［34］　FU J，SUN F，LIU W，LIU Y，GEDAM M，HU Q，et al.Subconjunctival delivery of dorzolamide-loaded poly(ether-anhydride) microparticles produces sustained lowering of intraocular pressure in rabbits［J］.Mol Pharm，2016，13(9):2987-2995.
［35］　LORENZ K，WASIELICA-POSLEDNIK J，BELL K，RENIERI G，KEICHER A，RUCKES C，et al.Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma［J］.PLoS One，2017，12(2):e171636.
［36］　NEWMAN-CASEY P A，ROBIN A L，BLACHLEY T，FARRIS K，HEISLER M，RESNICOW K，et al.The most common barriers to glaucoma medication adherence:a cross-sectional survey［J］.Ophthalmology，2015，122(7):1308-1316.
［37］　NEWMAN-CASEY P A，BLACHLEY T，LEE P P，HEISLER M，FARRIS K B，STEIN J D.Patterns of glaucoma medication adherence over four years of follow-up［J］.Ophthalmology，2015，122(10):2010-2021.
［38］　KIM M，KIM D M，PARK K H，KIM T W，JEOUNG J W，KIM S H.Intraocular pressure reduction with topical medications and progression of normal-tension glaucoma:a 12-year mean follow-up study［J］.Acta Ophthalmol，2013，91(4):E270-E275.

相似文献/References:

[1]李翔 谢钊 郭红建 谢学军 路雪婧 王毅 王超.补肾活血中药对大鼠慢性高眼压模型外侧膝状体病理改变的影响[J].眼科新进展,2012,32(1):000.
[2]彭坤 靳隽 杨玉新 许银霞 王保君 闫义涛 杨华.长期联合应用噻吗洛尔对结膜组织炎性标记物ICAM-1和HLA-DR表达的影响[J].眼科新进展,2012,32(6):000.
[3]赵宁 万超 刘宁宁 王建英 陈蕾 才娜.玻璃体切割联合超全视网膜光凝、白内障摘出术治疗新生血管性青光眼[J].眼科新进展,2012,32(6):000.
[4]沙英 刘黎明 孙勇 王绍飞 蒋晨 阿依努尔?艾买尔 陈星.联合激光虹膜切除术术后超声乳化晶状体摘出术治疗急性闭角型青光眼持续高眼压的疗效观察[J].眼科新进展,2012,32(6):000.
[5]王勇 叶应嘉 鲍先议 周龑丽 许荣 彭婷婷 曾志富.同轴微小切口超声乳化吸出术在青光眼滤过术后白内障摘出术中的应用[J].眼科新进展,2012,32(7):000.
[6]陈洁 王桂琴 白宗禧 洛桑 石晶 昌宏发 彭秀军.北京与西藏地区青壮年人群眼压分布特点比较[J].眼科新进展,2012,32(7):000.
[7]赵武校 蓝方方 刘伟民 黄建忠 罗武强 李志超.LASIK术后高眼压患者眼压与屈光状态之间变化关系的研究[J].眼科新进展,2012,32(11):000.
[8]叶长华 厉君 周丹 林丁.Ahmed青光眼阀植入术治疗硅油填充术后继发性青光眼的远期疗效[J].眼科新进展,2012,32(11):000.
[9]董敬民 张效房 马跃伟 王卫群 孔令训.曲伏前列素治疗原发性开角型青光眼的临床研究[J].眼科新进展,2012,32(12):000.
[10]李翔 马世勇 李娟 王毅.补肾活血中药对大鼠慢性高眼压模型视神经病理改变的影响[J].眼科新进展,2013,33(2):000.
[11]范虹 刘五存 蔡鸿英 赵堪兴.改良二极管激光睫状体光凝术治疗中晚期青光眼[J].眼科新进展,2012,32(4):000.
[12]王建萍 赵燕麟 马勇 朱涛 程燕 车选义 赵桂娥 王柯.噻吗洛尔和布林佐胺联合曲伏前列素治疗原发性开角型青光眼与高眼压患者的临床研究[J].眼科新进展,2012,32(5):000.
[13]马恩普 赵小钊 董良 刘苏冰 曾照年.Healaflow在青光眼小梁切除术中的应用[J].眼科新进展,2012,32(6):000.
[14]邱艳飞 何建中 何琼 王丽华 赖伟 钟敏.层间巩膜瓣切除联合小梁巩膜条转移治疗青光眼疗效观察[J].眼科新进展,2012,32(9):000.
[15]唐敏 傅扬 富名水 樊莹 郑志 孙晓东 许迅. 三种抗青光眼药物对选择性激光小梁成形术疗效的影响[J].眼科新进展,2014,34(1):054.
[16]张亦农. 抗青光眼术后中央角膜厚度变化及其与眼压的相关性研究[J].眼科新进展,2014,34(3):251.
[17]何伟华 独建库 李世洋. 小梁切除术后不同眼压对管状视野晚期青光眼患者预后的影响[J].眼科新进展,2014,34(3):275.
[18]李雯,周丹,厉君,等.眼轴长度对健康成年人24h眼压波动的影响[J].眼科新进展,2014,34(10):978.[doi:10.13389/j.cnki.rao.2014.0271]
[19]党鸿,辛晓蓉.青光眼视神经损伤机制的研究进展[J].眼科新进展,2016,36(7):680.[doi:10.13389/j.cnki.rao.2016.0181]
　DANG Hong,XIN Xiao-Rong.Research progress on optic nerve impairment mechanism in glaucoma[J].Recent Advances in Ophthalmology,2016,36(2):680.[doi:10.13389/j.cnki.rao.2016.0181]
[20]罗保根,张晓峰,钱一峰.角膜补偿眼压（IOPcc）和5种眼压校正公式所得校正眼压的一致性及IOPcc、模拟Goldmann眼压与眼球各参数的相关性分析[J].眼科新进展,2018,38(5):457.[doi:10.13389/j.cnki.rao.2018.0106]
　LUO Bao-Gen,ZHANG Xiao-Feng,QIAN Yi-Feng.Agreement between corneal-compensated intraocular pressure （IOPcc） and five corrected intraocular pressures and the correlation of ocular biometries with IOPcc and Goldmann correlated intraocular pressure[J].Recent Advances in Ophthalmology,2018,38(2):457.[doi:10.13389/j.cnki.rao.2018.0106]

更新日期/Last Update: 2019-02-18